The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. - Michaelis KA; Norgard MA; Zhu X; Levasseur PR; Sivagnanam S; Liudahl SM; Burfeind KG; Olson B; Pelz KR; Angeles Ramos DM; Maurer HC; Olive KP; et al. (Nature communications, 2019)